Marker Therapeutics, Inc.
MRKR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $27,928 | $48,450 | $22,205 | $72,700 |
| - Cash | $19,192 | $15,111 | $11,782 | $42,351 |
| + Debt | $0 | $0 | $7,617 | $11,868 |
| Enterprise Value | $8,735 | $33,338 | $18,040 | $42,217 |
| Revenue | $6,591 | $3,311 | $3,514 | $1,242 |
| % Growth | 99.1% | -5.8% | 183% | – |
| Gross Profit | -$6,877 | -$7,106 | -$8,455 | -$1,921 |
| % Margin | -104.3% | -214.6% | -240.6% | -154.7% |
| EBITDA | -$11,118 | -$11,792 | -$17,002 | -$38,716 |
| % Margin | -168.7% | -356.1% | -483.9% | -3,118% |
| Net Income | -$10,731 | -$8,237 | -$29,931 | -$41,879 |
| % Margin | -162.8% | -248.8% | -851.9% | -3,372.7% |
| EPS Diluted | -1.19 | -1.93 | -3.58 | -5.47 |
| % Growth | 38.3% | 46.1% | 34.6% | – |
| Operating Cash Flow | -$10,910 | -$16,440 | -$26,972 | -$27,280 |
| Capital Expenditures | $0 | $0 | $0 | -$3,131 |
| Free Cash Flow | -$10,910 | -$16,440 | -$26,972 | -$30,411 |